{"disease":{"id":"melanoma-stage-iv","name":"melanoma stage iv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT01274338","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1673,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02506153","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1301,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03677739","title":"Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1160,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04410445","title":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":765,"lead_sponsor_name":"Nektar Therapeutics","has_results":true},{"nct_id":"NCT02339571","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04593277","title":"Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05171374","title":"pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"MelanomaPRO, Russia","has_results":false},{"nct_id":"NCT03663647","title":"Advanced Melanoma in Russian Experience","phase":"","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"MelanomaPRO, Russia","has_results":false},{"nct_id":"NCT03698019","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05655312","title":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT07148245","title":"Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02196181","title":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":269,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02224781","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":267,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02374255","title":"Improving Goals of Care Discussion in Advanced Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04526899","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT06643286","title":"Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04079166","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT01950390","title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04990726","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04511013","title":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04248387","title":"Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06780397","title":"Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07155317","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03033576","title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06152367","title":"Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"University of Chile","has_results":false},{"nct_id":"NCT01708941","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05102773","title":"The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01258855","title":"Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05652673","title":"Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03025256","title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01127451","title":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT01989585","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05079113","title":"Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT00937937","title":"Dinaciclib in Treating Patients With Stage IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}